Acute Effect of Glibenclamide Upon Red Cell Transglutaminase Activity in Diabetic Patients

Overview

Journal J Endocrinol Invest

Publisher Springer

Specialty Endocrinology

Date 1987 Dec 1

PMID 2894389

Authors

M J Coves

R Gomis

J L Ribes

M A Arbos

R Casamitjana

E Vilardell

Affiliations

Soon will be listed here.

Abstract

The acute effect of glibenclamide, a hypoglycemic sulfonylurea, upon transglutaminase activity was investigated in 6 type II diabetic patients by perfusing 1 mg glibenclamide during 1 h. Blood samples were drawn 0, 10, 20, 30, 60 min during and 30 and 60 min after perfusion to determine insulin, glucose and transglutaminase activity. No significant modifications in plasma insulin, plasma glucose and transglutaminase activity in red cells was induced by glibenclamide perfusion. Nevertheless, glibenclamide induced a significant decrease (p less than 0.005) in transglutaminase activity after 20 min of perfusion (629.83 +/- 53.08 and 521.18 +/- 43.92, mean +/- SE, at 0 and 20 min). No correlation was observed between glucose or insulin plasma levels and transglutaminase activity.

References

Nowak S, McCaleb M, Lockwood D . Extrapancreatic action of sulfonylureas: hypoglycemic effects are not dependent on altered insulin binding or inhibition of transglutaminase. Metabolism. 1983; 32(4):398-402. DOI: 10.1016/0026-0495(83)90050-1. View

Folk J . Transglutaminases. Annu Rev Biochem. 1980; 49:517-31. DOI: 10.1146/annurev.bi.49.070180.002505. View

Sener A, Dunlop M, Gomis R, Mathias P, Malaisse-Lagae F, Malaisse W . Role of transglutaminase in insulin release. Study with glycine and sarcosine methylesters. Endocrinology. 1985; 117(1):237-42. DOI: 10.1210/endo-117-1-237. View

Davies P, Davies D, Levitzki A, Maxfield F, Milhaud P, Willingham M . Transglutaminase is essential in receptor-mediated endocytosis of alpha 2-macroglobulin and polypeptide hormones. Nature. 1980; 283(5743):162-7. DOI: 10.1038/283162a0. View

Paonessa G, Metafora S, Tajana G, Abrescia P, DE Santis A, Gentile V . Transglutaminase-mediated modifications of the rat sperm surface in vitro. Science. 1984; 226(4676):852-5. DOI: 10.1126/science.6149619. View

Gomis R, Sener A, Malaisse-Lagae F, Malaisse W . Transglutaminase activity in pancreatic islets. Biochim Biophys Acta. 1983; 760(3):384-8. DOI: 10.1016/0304-4165(83)90378-1. View

Gambhir K, Archer J, Bradley C . Characteristics of human erythrocyte insulin receptors. Diabetes. 1978; 27(7):701-8. DOI: 10.2337/diab.27.7.701. View

Levitzki A, Willingham M, Pastan I . Evidence for participation of transglutaminase in receptor-mediated endocytosis. Proc Natl Acad Sci U S A. 1980; 77(5):2706-10. PMC: 349472. DOI: 10.1073/pnas.77.5.2706. View

Gomis R, Mathias P, Lebrun P, Malaisse-Lagae F, Sener A, Malaisse W . Inhibition of transglutaminase by hypoglycaemic sulphonylureas in pancreatic islets and its possible relevance to insulin release. Res Commun Chem Pathol Pharmacol. 1984; 46(3):331-49. View

10.

Pfeifer M, Halter J, Judzewitsch R, Beard J, Best J, Ward W . Acute and chronic effects of sulfonylurea drugs on pancreatic islet function in man. Diabetes Care. 1984; 7 Suppl 1:25-34. View

11.

Schrier S, Junga I . The role of transglutaminase in human erythrocyte endocytosis. Biochem Biophys Res Commun. 1981; 99(1):58-64. DOI: 10.1016/0006-291x(81)91712-5. View

12.

Prince M, Olefsky J . Direct in vitro effect of a sulfonylurea to increase human fibroblast insulin receptors. J Clin Invest. 1980; 66(3):608-11. PMC: 371691. DOI: 10.1172/JCI109894. View

13.

Kolterman O, Olefsky J . The impact of sulfonylurea treatment upon the mechanisms responsible for the insulin resistance in type II diabetes. Diabetes Care. 1984; 7 Suppl 1:81-8. View